ASH 2021: A Phase 1 Dose Escalation Study of IGM-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies

63rd American Society of Hematology (ASH) Annual Meeting and Exposition – December 11-14, 2021 – Session: 623. Mantle Cell, Follicular, and Other B-Cell Lymphomas

SITC 2021: IGM-7354 is an anti-PD-L1 IgM antibody and IL-15 cytokine fusion that enhances NK and CD8+ T cell proliferation and tumor cytotoxicity plus potently reverses T cell exhaustion

The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting & Pre-Conference Programs – November 12-14, 2021

PEGS Europe 2021: Multimeric IgM Antibodies Targeting DR5 are Potent and Rapid Inducers of Tumor Cell Apoptosis In Vitro and In Vivo

PEGS Europe – November 4, 2021

AACR 2021: Mechanistic evaluation of anti-DR5 IgM antibody IGM-8444 with potent tumor cytotoxicity, without in vitro hepatotoxicity

American Association for Cancer Research (AACR) Annual Meeting 2021, Virtual – April 10-15, 2021 – Session: Therapeutic Mechanisms of Novel Anticancer Agent